Shares of ABIVAX Société Anonyme (NASDAQ:ABVX - Get Free Report) saw an uptick in trading volume on Friday . 243,086 shares were traded during trading, an increase of 160% from the previous session's volume of 93,390 shares.The stock last traded at $10.37 and had previously closed at $10.32.
Wall Street Analysts Forecast Growth
Separately, Laidlaw started coverage on ABIVAX Société Anonyme in a research report on Monday, July 29th. They set a "buy" rating and a $48.00 price objective for the company. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $36.50.
Get Our Latest Stock Analysis on ABIVAX Société Anonyme
ABIVAX Société Anonyme Stock Performance
The stock's 50 day simple moving average is $11.00 and its 200-day simple moving average is $12.50.
Institutional Investors Weigh In On ABIVAX Société Anonyme
Institutional investors have recently modified their holdings of the business. Capstone Investment Advisors LLC raised its holdings in shares of ABIVAX Société Anonyme by 9.0% during the first quarter. Capstone Investment Advisors LLC now owns 62,966 shares of the company's stock valued at $900,000 after acquiring an additional 5,199 shares during the last quarter. BNP Paribas Financial Markets acquired a new position in shares of ABIVAX Société Anonyme in the first quarter valued at approximately $81,000. Kennedy Capital Management LLC increased its position in shares of ABIVAX Société Anonyme by 35.3% during the first quarter. Kennedy Capital Management LLC now owns 120,168 shares of the company's stock worth $1,718,000 after acquiring an additional 31,331 shares during the period. Janus Henderson Group PLC boosted its stake in shares of ABIVAX Société Anonyme by 18.2% in the 1st quarter. Janus Henderson Group PLC now owns 851,839 shares of the company's stock valued at $12,113,000 after buying an additional 131,414 shares during the period. Finally, abrdn plc lifted its stake in ABIVAX Société Anonyme by 167.7% in the third quarter. abrdn plc now owns 316,431 shares of the company's stock worth $3,645,000 after acquiring an additional 198,225 shares during the last quarter. 47.91% of the stock is currently owned by institutional investors and hedge funds.
ABIVAX Société Anonyme Company Profile
(
Get Free Report)
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.
Further Reading
Before you consider ABIVAX Société Anonyme, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ABIVAX Société Anonyme wasn't on the list.
While ABIVAX Société Anonyme currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
